Search Results

Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and highly manageable. Olutasidenib represents a therapeutic advance for these patients with a poor prognosis. Olutasidenib received the […]

The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1 Standard of care therapy, which includes a maximal safe resection where possible, followed by focal radiation therapy, has remained unchanged for decades. This therapy, […]

Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]

The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use […]

Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1 UGI cancers are the seventh most frequently diagnosed cancer and the sixth most common cause of cancer-related death.1 In the USA, there were […]

Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy characterized by the presence of ≥20% blasts in bone marrow or peripheral blood or the presence of defined genetic abnormalities.1 In 2020, there were an estimated 21,450 new patients with AML and 11,180 AML-related deaths in the USA.2 Most mutated myeloid stem cells proliferate due to genetic alterations, […]

Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1 In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 deaths, respectively, in 2022 alone.2,3 GEC is divided based on the histology of squamous […]

Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et al. review data from the KEYNOTE-826 Phase III trial, which showed the benefits of adding pembrolizumab […]

Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1 CCAs tend to metastasize and have early lymph node involvement. As a result, only a small proportion of patients are considered for surgical management, […]